These Analysts Revise Their Forecasts On Argenx After Q4 Earnings - argenx (NASDAQ:ARGX)

Core Insights - Argenx SE reported strong fourth-quarter results, with earnings of $8.02 per share, exceeding the consensus estimate of $6.02, and sales increased from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion [1] - The company announced positive topline results from the Phase 3 ADAPT OCULUS study for VYVGART in adults with ocular myasthenia gravis [1] Financial Performance - Fourth-quarter earnings per share were $8.02, beating expectations [1] - Sales rose significantly from $761.2 million to $1.32 billion, exceeding analyst estimates [1] Product Development and Market Impact - VYVGART reached 19,000 patients globally, indicating successful market penetration [2] - The company expanded its impact in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) through the launch of a pre-filled syringe [2] - Progress was made in advancing the development pipeline towards key milestones [2] Stock Performance - Argenx shares closed at $771.53 following the earnings announcement [2] - Analysts adjusted their price targets for Argenx after the earnings report [2]